Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Lin, Zhuofeng ^a,e   Wu, Zhen ^b   Yin, Xiaojing ^b   Liu, Yanlong ^a,c   Yan, Xinxin ^a   Lin, Shaoqiang ^a   Xiao, Jian ^a   Wang, Xiaojie ^d   Feng, Wenke ^a,c   Li, Xiaokun ^a,d,e  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c University of Louisville School of Medicine   (United States)

^d JILIN AGRICULTURAL UNIVERSITY   (China)

^e Basic Medical College   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; C REACTIVE PROTEIN; CHOLESTEROL; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; FIBROBLAST GROWTH FACTOR;

AGED; ARTICLE; BODY MASS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; UNIVERSITY HOSPITAL; ANTHROPOMETRY; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; METABOLISM; METHODOLOGY; MIDDLE AGED; REGRESSION ANALYSIS;

ANIMALIA;

AGED; ANTHROPOMETRY; CASE-CONTROL STUDIES; CORONARY DISEASE; FEMALE; FIBROBLAST GROWTH FACTORS; GLUCOSE; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; TRIGLYCERIDES;

EID: 78650850911     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015534     Document Type: Article

References (30)

1. Jin K, LaFevre-Bernt M, Sun Y, Chen S, Gafni J, et al. (2005) FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci U S A 102: 18189-18194.
2. Ortega S, Ittmann M, Tsang SH, Ehrlich M, Basilico C (1998) Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc Natl Acad Sci U S A 95: 5672-5677.
3. Lin ZF, Li XK, Lin Y, Wu F, Liang LM, et al. (2005) Protective effects of nonmitogenic human acidic fibroblast growth factor on hydrogen peroxide-induced damage to cardiomyocytes in vitro. World J Gastroenterol 11: 5492-5497.
4. Beenken A Mohammadi M (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8: 235-253.
5. Fu X, Cuevas P, Gimenez-Gallego G, Tian H, Sheng Z (1996) Acidic fibroblast growth factor reduces renal morphologic and functional indicators of injury caused by ischemia and reperfusion. Wound Repair Regen 4: 297-303.
6. Fu X, Li X, Wang T, Cheng B, Sheng Z (2004) Enhanced anti-apoptosis and gut epithelium protection function of acidic fibroblast growth factor after cancelling of its mitogenic activity. World J Gastroenterol 10: 3590-3596.
7. Fu X, Cuevas P, Gimenez-Gallego G, Sheng Z, Tian H (1995) Acidic fibroblast growth factor reduces rat skeletal muscle damage caused by ischemia and reperfusion. Chin Med J (Engl) 108: 209-214.
8. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, et al. (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115: 1627-1635.
9. Fukumoto S (2008) Actions and mode of actions of FGF19 subfamily members. Endocr J 55: 23-31.
10. Nishimura T, Nakatake Y, Konishi M, Itoh N (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492: 203-206.
11. Nishimura T, Utsunomiya Y, Hoshikawa M, Ohuchi H, Itoh N (1999) Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta 1444: 148-151.
12. Jones S (2008) Mini-review: endocrine actions of fibroblast growth factor 19. Mol Pharm 5: 42-48.
13. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, et al. (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148: 774-781.
14. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, et al. (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149: 6018-6027.
15. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, et al. (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5: 426-437.
16. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, et al. (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5: 415-425.
17. Kliewer SA, Mangelsdorf DJ (2010) Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr 91: 254S-257S.
18. Li H, Bao Y, Xu A, Pan X, Lu J, et al. (2009) Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 94: 2151-2156.
19. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, et al. (2009) Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 71: 369-375.
20. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, et al. (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57: 1246-1253.
21. Stein S, Bachmann A, Lossner U, Kratzsch J, Bluher M, et al. (2009) Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care 32: 126-128.
22. Tan KC, Wat NM, Tam SC, Janus ED, Lam TH, et al. (2003) C-reactive protein predicts the deterioration of glycemia in chinese subjects with impaired glucose tolerance. Diabetes Care 26: 2323-2328.
23. Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K (2000) Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 20: 538-544.
24. Kuusisto J, Lempiainen P, Mykkanen L, Laakso M (2001) Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men. Diabetes Care 24: 1629-1633.
25. Chen WW, Li L, Yang GY, Li K, Qi XY, et al. (2008) Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 116: 65-68.
26. Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, et al. (2004) The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 42: 1355-1363.
27. Luc G, Bard JM, Ferrieres J, Evans A, Amouyel P, et al. (2002) Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol 22: 1155-1161.
28. Hotta Y, Nakamura H, Konishi M, Murata Y, Takagi H, et al. (2009) Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 150: 4625-4633.
29. Berglund ED, Li CY, Bina HA, Lynes SE, Michael MD, et al. (2009) Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 150: 4084-4093.
30. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, et al. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58: 250-259.